In Depth 13 Mar 2024 From LSD to healing minds: Where are we standing in psychedelic drug development? Delve into the growing sector of psychedelic drug development to find out where we are coming from, and where we are standing in the field. March 13, 2024 - 13 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 11 Mar 2024 Biotech bankruptcies: what to expect in 2024 following a record year? 2023 broke the record for the highest number of biotech bankruptcies in a decade. Can biotechs mitigate the risk in 2024? March 11, 2024 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 7 Mar 2024 Can AbbVie’s legacy live beyond its once best-selling drug Humira? The sales of AbbVie’s Humira, once a best-seller, have dropped. Now, with a new CEO announced, things are about to change for the company. March 7, 2024 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 6 Mar 2024 The biggest private biotech investments in February 2024 The companies BioAge Labs, Latigo Biotherapeutics, and Neurona Therapeutics bagged the biggest private biotech investments in February 2024. March 6, 2024 - 3 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 28 Feb 2024 Beyond fundraising: how do venture capitals build early-stage biotechs? Venture capitals can help build early-stage biotech startups and boost innovation in the life science industry. February 28, 2024 - 6 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 27 Feb 2024 Can the Novo Holdings-Catalent deal set a new standard for Pharma M&A? Explore the strategic implications of Novo Nordisk’s $16.5B Catalent acquisition on drug supply and market competition. February 27, 2024 - 7 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 22 Feb 2024 TIL therapies: the impact on cancer research The approval of the first-ever TIL therapy has made it possible to treat hundreds of thousands of people affected by skin cancer in the US. February 22, 2024 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 21 Feb 2024 Cytokine release syndrome: how pharma is tackling a 21st century disease Explore the frontier of biotech’s battle against cytokine release syndrome (CRS), from historical setbacks to cutting-edge solutions. February 21, 2024 - 6 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
In Depth 15 Feb 2024 Turning the tide: recent advancements in childhood cancer research As we observe International Childhood Cancer Day today, let us take a look at some of the recent advancements in childhood cancer research. February 15, 2024 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 15 Feb 2024 Biogen: how is the biotech giant pivoting from a failed Alzheimer’s drug? Learn more about Biogen’s strategic realignment from Aduhelm’s controversy to Leqembi’s promise in Alzheimer’s treatment. February 15, 2024 - 11 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 14 Feb 2024 The next leap in pet health: longevity drugs for dogs Find out how we could stave off the heartbreak of saying goodbye to our dogs, as three longevity drugs for dogs could soon be approved. February 14, 2024 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 12 Feb 2024 RNA editing set to take off: could DNA’s short-lived cousin overcome the limitations of CRISPR gene editing? Find out all about about RNA editing, as two candidates have just managed to reach the clinic for the first time. February 12, 2024 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email